However, studies of the role of ErbB2 in clinical prostate cancer remain inconclusive (Grossmann et al, 2001), and initial clinical trials indicate that the anti-ErbB2 antibody Herceptin (trastuzumab) does not show significant clinical activity as a single agent (Ziada et al, 2004). Here, ERBB2 is linked to Familial prostate cancer.